



FULLY INTEGRATED PHARMACEUTICAL COMPANY



PHARMACEUTICALS

HIGH POTENT

BIOTECHNOLOGY

CONSUMER HEALTH

From research and development to specialized manufacturing,
commercialization and global partnerships.

50+

YEARS OF EXPERIENCE

40+

EXPORT MARKETS

210+

PRODUCTS

www.ilko.com.tr

SCAN THE QR TO JOIN
THE WORLD OF ILKO



Shaping the Future with Science

Value-added generics, high-potent products, biotechnology and consumer health - powered by strong R&D and modern manufacturing.



Rx

Value-added generics



HIGH POTENT PRODUCTS

Specialized non-sterile production



BIOTECHNOLOGY

Next-generation biologics



CONSUMER HEALTH

Science-backed wellbeing

ILKO Pharmaceuticals builds on more than 50 years of pharmaceutical experience and heritage. Established in 2012 under Selçuklu Holding, the company combines research, development, manufacturing and commercial capabilities within one integrated platform.



50+

years of pharmaceutical experience

210+

products across the portfolio

100+

different molecules

25,000 m²

manufacturing area

120 M

annual box capacity

2,600 m²

high-potent production area

1,000+

employees

40+

countries with export activity

END-TO-END CAPABILITY

Fully Integrated Pharmaceutical Company

An integrated network connecting R&D, biotechnology, manufacturing, commercial operations and international partnerships.



HEAD OFFICE

Rx, biotech and
consumer health
management



HIGH-POTENT SITE

Specialized non-sterile
production and
CMO



R&D CENTER

Value-added small
molecules and
delivery systems



BIOTECH CENTER

Biosimilars, biologics and
advanced
process platforms

ONE NETWORK FIVE PARTNERSHIP MODELS

DISTRIBUTORSHIP

IN / OUT LICENSING

CO-DEVELOPMENT

CMO / CDMO

TECH TRANSFER

From Molecule to Medicine

Next-generation biologics and biosimilars developed through purpose-built science, advanced platforms and international collaboration.

Pioneering since 2013

Türkiye's first biotechnology company, founded as a joint venture between ILKO and Genexine.

Focus areas

Oncology and autoimmune diseases, with a pipeline of next-generation biologics and biosimilars.

End-to-end capabilities

Cell line development, upstream and downstream processing, analytics, quality control and stability studies.



BIOTECHNOLOGICAL PIPELINE AT A GLANCE

First-in-Class Trial: Completed Phase II clinical trial of GX-G3 for chemotherapy-induced neutropenia.

Advanced Biotech Facility: Over 10 years of expertise at ILKO Biotechnology Center with a stable CHO cell line.

End-to-End Capabilities: From cell line development to downstream processing, analytics, and stability studies.

Innovation-Driven: High-efficiency production and cost-effective biologics for global healthcare challenges.

PRODUCT	CLASS	TREATMENT AREA	RESEARCH	CLINICAL PHASE			
				PRE-CLINICAL	I	II	III
GX-G3 (3rd generation filgrastim developed by hyFc technology)	Biobetter	CIN*					
Bevacizumab	Biosimilar	Oncology					
Nivolumab	Biosimilar	Oncology					
Pembrolizumab	Biosimilar	Oncology					

CIN*: Chemotherapy induced neutropenia

10+ YEARS

biotech development expertise
Stable CHO cell line and advanced
process know-how

PHASE II

GX-G3 clinical milestone completed
Chemotherapy-induced neutropenia



WellcareTM

The art of living healthy

SCIENCE-BACKED FORMULATIONS FOR LIFELONG VITALITY


- Scientific, clean-label formulations

- Clinical evidence and health authority approvals

- PIC/S & GMP-compliant; ISO 9001 & ISO 13485 certified

- Wellbeing support across every stage of life

A COMPLETE CONSUMER HEALTH PLATFORM



VITAMINS
& MINERALS



LONGEVITY



COGNITIVE
HEALTH



GROWTH &
DEVELOPMENT



SPORTS
SUPPLEMENT
& MOBILITY



DIGESTIVE
HEALTH



PROBIOTICS



SPECIAL
SUPPLEMENTS



WOMEN'S
HEALTH



NASAL
HEALTH



COUGH & COLD



Rx
PRODUCTS



OMEGA-3



BEAUTY
FROM WITHIN



YOU CAN VIEW THE WELLCARE PRODUCT PORTFOLIO HERE

INTERNATIONAL BUSINESS

Your Trusted Partner in Global Healthcare Markets

A flexible partnership platform supporting export, strategic cooperation and long-term market development.

40+
COUNTRIES

**GLOBAL EXPORT AND
STRATEGIC COOPERATION**



BUSINESS MODELS



Pharmaceutical Products

A0 Alimentary Tract & Metabolism | B0 Blood + B. Forming Organs | C0 Cardiovascular System

ATC 1	A0 ALIMENTARY TRACT & METABOLISM		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
A02 A-ACID A-FLAT A-ULCERANTS	Famotidine / Calcium Carbonate / Magnesium Hydroxide	10 mg / 800 mg / 165 mg	2 & 6 & 12 Chewable Tablet
	Lansoprazole	15 mg	30 Enteric Micropellet Capsule
	Pantoprazole Sodium Sesquihydrate	30 mg	14 & 28 Enteric Micropellet Capsule
	Rabeprazole Sodium	40 mg	14 & 28 Enteric Coated Tablet
	Rabeprazole Sodium	20 mg	14 & 28 Enteric Coated Tablet
	Sodium Alginate / Magnesium Alginate	225 mg / 87,5 mg	30 Sachet
	Sodium Alginate / Potassium Bicarbonate	1000 mg + 200 mg / 10 mL	200 mL Oral Suspension
	Sodium Alginate / Sodium Bicarbonate / Calcium Carbonate	500 mg / 267 mg / 160 mg	30 & 60 Chewable Tablet
A04 ANTIEMETICS* ANTINAUSEANTS	Doxylamine Succinate / Pyridoxine HCl	500 mg + 267 mg + 160 mg / 10 mL	200 mL Oral Suspension
A05 BILIARY TR & LIVER DIS PRD	Sodium Bicarbonate	500 mg	100 Enteric Coated Tablet
A06 DRUGS FOR CONSTIPATION	Macrogol 3350 / Sodium Chloride / Sodium Bicarbonate / Potassium Chloride	10 mg / 10 mg	30 Film Coated Tablet
		250 mg	100 Capsule
A07 INTESTINAL DISORDER PROD	Mesalazine	13,125 g / 0,35 g / 0,18 g / 0,04 g	10 & 20 & 30 Sachets Oral Suspension
		6,56 g / 0,17 g / 0,09 g / 0,02 g	20 & 30 Sachets-Pediatric Oral Suspension
		250 mg	10 & 30 Suppository
	Racecadotril	500 mg	30 Suppository
		4 g / 60 mL	7 Rectal Suspension
		10 mg	16 Orodispersible Tablet
	Rifaximin	30 mg	30 Orodispersible Tablet
		100 mg	20 Capsule
		200 mg	12 Film Coated Tablet
	Sitagliptin / Metformin HCl	550 mg	56 Film Coated Tablet
A10 DRUGS USED IN DIABETES	Dapagliflozin	5 mg & 10 mg	28 & 90 Film Coated Tablet
	Metformin Hydrochloride	850 mg & 1000 mg	100 Film Coated Tablet
	Sitagliptin HCl	25 mg & 50 mg & 100 mg	28 Film Coated Tablet
	Sitagliptin / Metformin HCl	50 mg / 500 mg	56 XR Tablet
		50 mg / 1000 mg	
		100 mg / 1000 mg	
	Repaglinide / Metformin HCl	1 mg / 500 mg	90 Film Coated Tablet
		2 mg / 500 mg	
	Vildagliptin	50 mg	28 & 56 Tablet
	Vildagliptin / Metformin HCl	50 mg / 850 mg	60 Film Coated Tablet
		50 mg / 1000 mg	
A11 VITAMINS	Colecalciferol (Vitamin D3)	150.000 IU / 15 mL	15 mL Oral Drop
		300.000 IU / 20 mL	20 mL Oral Drop
A16 OTHER METABOLIC PRODUCTS	Sapropterin HCl	100 mg	30 Dispersible Tablet
	Alpha Lipoic Acid (Thioctic Acid)	600 mg	30 Film Coated Tablet
ATC 1	B0 BLOOD + B. FORMING ORGANS		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
B02 BLOOD COAGULAT SYST PRD	Eltrombopag	25 mg & 50 mg & 75 mg	14 Film Coated Tablet
B01 ANTITHROMBOTIC AGENTS	Ticagrelor	60 mg & 90 mg	56 Film Coated Tablet
ATC 1	C0 CARDIOVASCULAR SYSTEM		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
C05 TOPICAL ANTIHAEMORRHOIDAL	Diltiazem Hydrochloride	2 %	30 g Tube Cream
C07 BETA BLOCKING AGENTS	Metoprolol Succinate	25 mg & 50 mg	20 & 30 CR Film Coated Tablet
		100 mg	20 CR Film Coated Tablet
		5 mg	28 & 84 Tablet
	Nebivolol Hydrochlorothiazide	10 mg	28 Tablet
C09 RENIN-ANGIOTEN SYST AGENT	Irbesartan	150 mg & 300 mg	28 Film Coated Tablet
		150 mg / 12,5 mg	28 Film Coated Tablet
	Irbesartan / Hydrochlorothiazide	300 mg / 12,5 mg	
		300 mg / 25 mg	
	Telmisartan / Hydrochlorothiazide	80 mg / 12,5 mg	28 Film Coated Tablet
		80 mg / 25 mg	
	Valsartan	80 mg & 160 mg & 320 mg	28 Film Coated Tablet
		160 mg / 5 mg	28 Film Coated Tablet
	Valsartan / Amlodipine Besilate	160 mg / 10 mg	
		80 mg / 12,5 mg	28 Film Coated Tablet
	Valsartan / Hydrochlorothiazide	160 mg / 12,5 mg	
		160 mg / 25 mg	
		320 mg / 12,5 mg	
		320 mg / 25 mg	
C10 LIPID-REG / A-ATHEROMA PRD	Verapamil HCl / Trandolapril	180 mg / 2 mg	28 Film Coated Tablet
		240 mg / 4 mg	
	Colesevelam Hydrochloride	625 mg	180 Film Coated Tablet
	Fenofibrate	45 mg & 135 mg	30 & 90 DR Hard Capsule
	Rosuvastatin Calcium	10 mg & 20 mg & 40 mg	28 & 90 Film Coated Tablet

Pharmaceutical Products

D0 Dermatologicals | G0 G.U. System | H0 Hormones | J0 Anti-infectives | L0 Oncology | M0 Musculoskeletal

ATC 1	D0 DERMATOLOGICALS		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
D04A ANTIPRURITICS	Mepyramine Maleate / Lidocaine HCl / Dexpanthenol	1,5 % / 1,5 % / 5 %	30 g Tube Gel
D05 NON-STER PRD INFLAM SKIN	Calcipotriol Monohydrate / Betamethasone Dipropionate	0,005 % + 0,05 %	30 g Tube Ointment
D06 TOP A-BACTS & A-VIRALS	Aciclovir / Hydrocortisone	5 % + 1 %	5 g Tube Cream
	Fusidic Acid	2 %	20 g Tube Cream
D07 TOPICAL CORTICOSTEROIDS	Clobetasol -17- Propionate	0,05 %	50 g Tube Gel
			50 g Ointment
			50 g Cream
	Hydrocortisone Acetate / Pramoxine	1 % + 1 %	30 g Tube Cream
		2,5 % + 1 %	
	Hydrocortisone -17- Butyrate	0,10 %	30 g Tube Cream
D10 ANTI-ACNE PREPARATIONS	Halometasone / Fusidic Acid	0,05 % + 2 %	30 g Tube Cream
	Dapsone	5 % & 7,5 %	30 g Tube Gel

ATC 1	G0 G. U. SYSTEM & SEX HORMONES		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
G04 UROLOGICALS	Dapoxetine HCl	30 mg & 60 mg	3 & 6 Film Coated Tablet
	Solifenacin Succinate	5 mg & 10 mg	30 & 90 Film Coated Tablet
	Tadalafil	5 mg	14 & 28 Film Coated Tablet
		20 mg	2 & 4 & 8 Film Coated Tablet

ATC 1	H0 SYSTEMIC HORMONES		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
H02 SYSTEMIC CORTICOSTEROIDS	Prednisone	1 mg & 2 mg & 5 mg	30 DR Tablet
H05 OTHER ANTI-PARATHYROID DRUG	Cinacalcet Hydrochloride	30 mg & 60 mg & 90 mg	28 Film Coated Tablet

ATC 1	J0 SYSTEMIC ANTI-INFECTIVES		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
J01 SYSTEMIC ANTIBACTERIALS	Levofloxacin Hemihydrate	500 mg / 100 mL	100 mL Solution for Infusion Vial
		500 mg & 750 mg	7 Film Coated Tablet
	Moxifloxacin HCl	400 mg	7 Film Coated Tablet
		300 mg	10 & 20 Film Coated Tablet
	Cefdinir	600 mg	7 & 10 & 14 Film Coated Tablet
		125 mg / 5 mL & 250 mg / 5 mL	100 mL Oral Suspension Dry Powder
J05 ANTIVIRALS SYSTEMIC USE	Cefixime	400 mg	5 & 10 Film Coated Tablet
	Entecavir	0,5 mg & 1 mg	30 Film Coated Tablet
	Oseltamivir	75 mg	10 Capsule
	Tenofovir Disoproxil Fumarate	245 mg	30 Film Coated Tablet
	Tenofovir Disoproxil Fumarate / Emtricitabine	200 mg / 245 mg	30 Film Coated Tablet

ATC 1	L0 ANTINEOPLASTICS + IMMUNOMODULATORY AGENTS		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
L01 ALL OTH. ANTINEOPLASTICS	Anagrelide Hydrochloride	0,5 mg	100 Hard Capsule
L04 IMMUNOSUPPRESSANTS	Tofacitinib Citrate	5 mg	56 Film Coated Tablet

ATC 1	M0 MUSCULO-SKELETAL SYSTEM		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
M01 ANTIRHEUMATIC SYSTEM	Dexketoprofen Trometamol	25 mg	20 Film Coated Tablet
		50 mg / 2 mL	2 mL Solution of Injection 6 Vial
	Flurbiprofen	100 mg	15 & 30 Film Coated Tablet
		200 mg	16 SR Micropellet Capsule
M02 ANTIRHEUMATICS TOPICAL	Ibuprofen / Famotidine	800 mg / 26,6 mg	14 & 30 & 90 Film Coated Tablet
	Ibuprofen / Levomenthol	5 % + 3 %	60 g Tube Gel
M03 MUSCLE RELAXANTS	Thiocolchicoside / Dexketoprofen Trometamol	4 mg / 25 mg	20 Film Coated Tablet
		8 mg / 25 mg	14 Film Coated Tablet

Pharmaceutical Products

N0 Nervous System | R0 Respiratory System | V0 Various

ATC 1	N0 NERVOUS SYSTEM		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
N01 ANAESTHETICS	Lidocaine / Tetracaine	7 %	10 g & 30 g Tube Cream
N02 ANALGESICS	Morphine Sulfate	15 mg	30 & 60 Tablet
		30 mg	30 Tablet
		15 mg & 30 mg & 60 mg & 100 mg	20 CR Film Coated Tablet
	Pregabalin	75 mg	14 & 42 & 56 Capsule
		25 mg & 150 mg & 225 mg & 300 mg	56 Capsule
N03 ANTI-EPILEPTICS	Sumatriptan Succinate / Naproxen Sodium	85 mg / 500 mg	2 & 4 & 6 & 9 Film Coated Tablet
	Levetiracetam	250 mg & 500 mg & 750 mg & 1000 mg	50 Film Coated Tablet
N04 ANTI-PARKINSON PREPS	Levodopa / Carbidopa	25 mg / 100 mg & 50 mg / 200 mg	30 & 100 SR Tablet
	Levodopa / Carbidopa / Entacapone	50 mg / 12,5 mg / 200 mg	100 Film Coated Tablet
		75 mg / 18,75 mg / 200 mg	
		100 mg / 25 mg / 200 mg	
		125 mg / 31,25 mg / 200 mg	
		150 mg / 37,5 mg / 200 mg	
		200 mg / 50 mg / 200 mg	
	Rasagiline Mesilate	1 mg	30 Tablet
N05 PSYCHOLEPTICS	Melatonin	3 mg	30 Film Coated Tablet
	Quetiapine Fumarate	25 mg & 100 mg	30 Film Coated Tablet
		50 mg & 150 mg & 200 mg & 300 mg & 400 mg	30 & 60 Film Coated Tablet
		50 mg	30 Extended Release Tablet
		150 mg & 200 mg & 300 mg & 400 mg	30 & 60 Extended Release Tablet
	Risperidone	1 mg & 2 mg & 3 mg & 4 mg	20 Film Coated Tablet
		1 mg / mL	100 mL Oral Solution
N06 PSYCHOANALEPTICS	Duloxetine HCl	30 mg & 60 mg	28 Capsule
	Venlafaxine HCl	37,5 mg	14 & 28 XR Micropellet Capsule
		75 mg & 150 mg	28 XR Micropellet Capsule
	Donepezil HCl	5 mg	14 & 28 Film Coated Tablet
		10 mg	28 Film Coated Tablet
	Donepezil HCl / Memantine HCl	10 mg / 7 mg	28 Extended Release Hard Capsule
		10 mg / 14 mg	
		10 mg / 21 mg	
		10 mg / 28 mg	
N07 OTHER CNS DRUGS	Teriflunomide HCl	14 mg	28 Film Coated Tablet
N07A0 MULTIPLE SCLEROSIS PRODS			

ATC 1	R0 RESPIRATORY SYSTEM		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
R03 ANTI-ASTHMA & COPD PROD	Levocetirizine Dihydrochloride / Montelukast Sodium	5 mg / 10 mg	30 & 90 Film Coated Tablet
	Montelukast Sodium	10 mg	28 & 84 Film Coated Tablet
R05 COUGH & COLD PREPARATIONS	Levodropropizine	4 mg & 5 mg	28 Chewable Tablet
		30 mg / 5 mL	150 mL Syrup
	Levocloperastine Fendizoate	708 mg / 100 mL	100 mL & 200 mL Oral Suspension
	Paracetamol / Pseudoephedrine HCl / Chlorpheniramine Maleate	650 mg / 60 mg / 4 mg	20 Film Coated Tablet
		650 mg / 30 mg / 4 mg	20 & 30 Film Coated Tablet
R06 ANTIHISTAMINES SYSTEMIC	Desloratadine	2,5 mg / 5 mL	150 mL Syrup
		5 mg	20 Film Coated Tablet
	Levocetirizine Dihydrochloride	0,5 mg / mL	200 mL Oral Solution
		5 mg	20 Film Coated Tablet
	Rupatadine Fumarate	10 mg	20 Tablet

ATC 1	V0 VARIOUS		
ATC 2/3/4	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM
V03 OTHER THERAPEUTIC PRODS	Polystyrene Sulfonate Calcium Salt	880 mg / g	20 & 60 & 120 Granule Sachet
V03G1 HYPERKALAEMIA PRODUCTS			
V03 OTHER THERAPEUTIC PRODS	Deferasirox	125 mg & 250 mg & 500 mg	28 Dispersible Tablet
V03F0 IRON-CHELATING AGENTS		90 mg & 180 mg & 360 mg	30 Film Coated Tablet

Under Registration - Rx

Marketing Authorization Timelines

ATC 1	A0 ALIMENTARY T. & METABOLISM			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	EXPECTED MA DATE
A10 DRUGS USED IN DIABETES A10P SGLT2 INHIBITOR A-DIABS	Empagliflozin	10 mg & 25 mg	30 Film Coated Tablet	2027 Q3
	Empagliflozin / Metformin	5 mg / 850 mg	60 Film Coated Tablet	2028 Q1
		5 mg / 1000 mg		
		12,5 mg / 850 mg		
A11 VITAMINS A11D4 VIT.B1+VIT.B6 &/OR B12	Cyanocobalamin / Pyridoxine / Thiamine	250 mg / 250 mg / 1 mg	30 & 50 Film Coated Tablet	2028 Q1

ATC 1	B0 BLOOD + B. FORMING ORGANS			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	EXPECTED MA DATE
B03 ANTIANAEIMICS	Iron (II) Glycine Sulfate Complex Pellets	100 mg	30 Enteric Hard Capsule	2027 Q2
	Iron (II) Glycine Sulfate / Folic Acid / Vitamin B12 (Cyanocobalamin)	100 mg / 0,5 mg / 2,5 mcg	30 Hard Capsule	2027 Q4

ATC 1	C0 CARDIOVASCULAR SYSTEM			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	EXPECTED MA DATE
C09 RENIN-ANGIOTEN SYST AGENT	Sacubitril / Valsartan	24 mg / 26 mg	28 Film Coated Tablet	2028 Q1
		49 mg / 51 mg	56 Film Coated Tablet	
		97 mg / 103 mg		

ATC 1	J0 SYSTEMIC ANTI - INFECTIVES			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	EXPECTED MA DATE
J05 ANTIVIRALS SYSTEMIC USE	Oseltamivir	12 mg / mL	75 mL Oral Suspension	2028 Q2
	Tenofovir Alafenamide Monofumarate	25 mg	30 Film Coated Tablet	2028 Q4

ATC 1	N0 NERVOUS SYSTEM			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	EXPECTED MA DATE
N04 ANTI-PARKINSON PREPS	Levodopa / Benserazide	100 mg / 25 mg	30 Tablet	2027 Q3
		200 mg / 50 mg		

All dossiers are ready and available in CTD/eCTD format.

For Zone IV stability details, please contact our export department.

None of the products will be supplied to countries in which this could be in conflict with existing patents. However the final responsibility lies exclusively with the buyer.

Registration & Development

High-potent oncology portfolio progressing through registration and development

UNDER REGISTRATION - ONCOLOGY

ATC 1	L0 ANTINEOPLASTICS + IMMUNOMODULATORY AGENTS			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	EXPECTED MA DATE
L01 ANTINEOPLASTICS	Dasatinib	20 mg	60 Film Coated Tablet	2027 Q4
		50 mg		
		70 mg		
		100 mg	30 Film Coated Tablet	
		140 mg		
	Erlotinib	100 mg	30 Tablet	2028 Q3
		150 mg		
	Palbociclib	75 mg	7 & 21 Tablet	2028 Q1
		100 mg		
		125 mg		
	Ruxolitinib	5 mg	14 & 56 & 168 Tablet	2027 Q2
		10 mg	56 & 168 Tablet	
		15 mg	14 & 56 & 168 Tablet	
		20 mg		
	Sorafenib	200 mg	112 Film Coated Tablet	2027 Q4
	Sunitinib	12,5 mg	28 Capsule	2028 Q1
		25 mg		
		50 mg		

UNDER DEVELOPMENT - ONCOLOGY

ATC 1	L0 ANTINEOPLASTICS + IMMUNOMODULATORY AGENTS			
ATC 2	ACTIVE INGREDIENT	STRENGTH	PACKAGING SIZE & FORM	CTD DOSSIER AVAILABILITY DATE
L01 ANTINEOPLASTICS	Cabozantinib (S) - malate	20 mg	30 Film Coated Tablet	2027 Q4
		40 mg		
		60 mg		
		80 mg		
	Olaparib	100 mg	56 & 112 Film Coated Tablet	2027 Q4
		150 mg		
	Osimertinib	40 mg	28 Film Coated Tablet	2027 Q4
		80 mg		
	Ribociclib	200 mg	63 Film Coated Tablet	2027 Q2
	Venetodax	10 mg	14 Film Coated Tablet	2027 Q4
50 mg		7 Film Coated Tablet		
100 mg		7 & 14 & 112 Film Coated Tablet		
L02 CYTOSTATIC HORMONE THERAPY	Enzalutamide	40 mg	112 Tablet	2027 Q4
		80 mg		



LET'S SHAPE THE FUTURE OF HEALTHCARE TOGETHER



For business enquiries, please contact us at
export@ilko.com.tr
bd@ilko.com.tr

Veysel Karani Mah. Çolakoğlu Sk. No:10
Rings Rezidans, Kat:7-8-9 34885, Sancaktepe
İstanbul/TÜRKİYE
Phone: +90 216 564 80 00
www.ilko.com.tr

SCAN THE QR TO JOIN
THE WORLD OF ILKO

